Remove 2025 Remove Healthcare Remove Physicians
article thumbnail

The Proposed 2025 Medicare Physician Fee Schedule Has Arrived! Key Takeaways for Digital Health Innovators

Nixon Gwilt Law

The 2025 Medicare Physician Fee Schedule Proposed Rule (the “2025 Proposed Rule”) issued by the Centers for Medicare and Medicaid Services (or “CMS”) on July 10, 2024 contains a number of new policy proposals with significant implications for healthcare innovators.

article thumbnail

Empowering Chief Medical Officers: Key Insights at the 2025 Healthcare CMO Summit

PM360

The 2025 Healthcare CMO Summit is an exclusive invitation-only event designed to bring together Chief Medical Officers (CMOs) and innovative suppliers and solution providers. AI in Healthcare and Informatics: Navigating AI’s role in decision-making and workforce efficiency.

Medical 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

op Pharma Marketing Trends Shaping the Future of Healthcare in 2025

Pharma Marketing Network

As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. With the increasing digitization of healthcare, pharmaceutical companies are leveraging digital platforms to reach broader audiences more effectively.

article thumbnail

Adopting AI for R&D in 2025 – what needs to be addressed?

European Pharmaceutical Review

However, the road to successful implementation is fraught with concerns around data privacy, workflow integration, and acceptance by both patients and physicians, stated Sachin Gharat, Associate Project Manager, Pharma at GlobalData. In 2025, organisations must focus on addressing data integrity challenges. 2024; 177: 108632.

article thumbnail

Are new weight loss drugs an answer or problem?

World of DTC Marketing

A Harvard study found that almost half of Americans are expected to be obese by 2030, accounting for up to 18 percent of healthcare spending on related conditions, ranging from heart disease and stroke to osteoarthritis. . Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025.

article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes.

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Both the physician and the patient have to be registered and the drugs can only come from a primary source through limited distribution. For Avadel’s Lumryz, the one-dose extended-release oral suspension that allows narcolepsy patients to sleep through the night, the worst-case scenario is it won’t be on the market until 2025.